WASHINGTON, June 20, 2019 /PRNewswire/ -- The
Antimicrobials Working Group (AWG), a coalition of companies with
the mission to combat drug-resistant infections and spur
life-saving innovations, today announced that eleven of its member
companies will present data from their clinical and research
programs at ASM Microbe 2019 to be held June
20 - 24 in San Francisco,
CA.
ASM Microbe showcases the best microbial sciences in the world
and provides a one-of-a-kind forum to explore the complete spectrum
of microbiology from basic science to translation and
application.
"ASM Microbe is an excellent opportunity for AWG Member
Companies to join with microbial scientists from around the world
and highlight innovations to combat drug-resistant infections,"
said Evan Loh, M.D., President,
Chief Operating Officer, and Chief Medical Officer of Paratek
Pharmaceuticals and Chairman of the AWG. "AWG companies will
highlight progress in their clinical and research programs in
antifungal, antibacterial, and non-traditional therapies in 64
presentations during the conference. These efforts underscore the
coalition's commitment to addressing the dire need for new
antimicrobial medicines for serious and life-threatening infectious
diseases."
The following AWG member companies will be presenting at ASM
Microbe 2019: Amplyx Pharmaceuticals, Cidara Therapeutics,
Contrafect Corporation, Entasis Therapeutics, Iterum Therapeutics,
Nabriva Therapeutics, Paratek Pharmaceuticals, Qpex Biopharma,
SCYNEXIS, Summit Therapeutics, and VenatoRx Pharmaceuticals.
For more information on AWG member company presentations and
access to specific abstracts, please visit:
https://www.antimicrobialsworkinggroup.org/asmmicrobe2019/
About The Antimicrobials Working Group
AWG was founded in 2012 with the vision of utilizing collective
power to improve the regulatory, investment, and commercial
environment for emerging infectious disease companies. Today, AWG
is comprised of thirteen antimicrobials companies: Amplyx
Pharmaceuticals, Aridis Pharmaceuticals, Cidara Therapeutics Inc.
(NASDAQ: CDTX), ContraFect Corporation (NASDAQ: CFRX), Entasis
Therapeutics Inc. (NASDAQ: ETTX), Iterum Therapeutics Ltd. (NASDAQ:
ITRM), Melinta Therapeutics Inc. (NASDAQ: MLNT), Nabriva
Therapeutics US Inc. (NASDAQ: NBRV), Paratek Pharmaceuticals Inc.
(NASDAQ: PRTK), Qpex Biopharma, Inc., SCYNEXIS Inc. (NASDAQ: SCYX),
Summit Therapeutics plc (NASDAQ: SMMT; AIM: SUMM), and VenatoRx
Pharmaceuticals, Inc.
For more information, visit:
www.antimicrobialsworkinggroup.org
About The Conafay Group
The Conafay Group, led by Stephen R.
Conafay, Principal, is a life-sciences government relations
firm based in Washington D.C. that
serves as Washington counsel and
coalition manager for AWG.
For more information, visit: www.conafaygroup.com
View original
content:http://www.prnewswire.com/news-releases/antimicrobials-working-group-highlights-member-company-participation-at-asm-microbe-2019-300871777.html
SOURCE Antimicrobials Working Group (AWG)